Intercept Pharmaceuticals, Inc. Logo

Press releases

Date Title and Summary View
Toggle Summary Intercept Announces Updated U.S. Prescribing Information for Ocaliva® (obeticholic acid) to Reinforce Appropriate Dosing in PBC Patients with Advanced Cirrhosis View HTML
Toggle Summary Intercept to Present at Upcoming Conference
NEW YORK, Dec. 07, 2017 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced management will be participating in the
View HTML
Toggle Summary Intercept Pharmaceuticals Appoints Christian Weyer as Executive Vice President of Research & Development
NEW YORK, Nov. 27, 2017 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced the appointment of Christian Weyer, M.D.,
View HTML
Toggle Summary Intercept Pharmaceuticals Reports Third Quarter 2017 Financial Results and Provides Business Update
Worldwide net Ocaliva ® (obeticholic acid or OCA) 3Q 2017 sales of $40.9 million (including one-time increase of $4.1M in deferred net revenue ) Continuing to advance NASH Phase 3 program: REGENERATE trial in NASH fibrosis on track and NASH cirrhosis trial to initiate by year end 2017   Conference
View HTML
Toggle Summary Intercept to Report Third Quarter 2017 Financial Results on November 1 and Present at Upcoming Conference
NEW YORK, Oct. 25, 2017 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced that it will report its third quarter 2017
View HTML
Toggle Summary Intercept Announces Positive Results from Phase 2 AESOP Trial Evaluating OCA for the Treatment of Patients with Primary Sclerosing Cholangitis at The Liver Meeting® 2017
OCA met the primary endpoint of alkaline phosphatase (ALP) reduction at 24 weeks Results presented in a late-breaking oral session NEW YORK, Oct. 23, 2017 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization
View HTML
Toggle Summary Intercept Announces Data to be Presented at The Liver Meeting® 2017
Results from the Phase 2 AESOP Trial in Primary Sclerosing Cholangitis to be Presented in Late Breaking Oral Session
View HTML
Toggle Summary Intercept Statement Regarding Ocaliva® (obeticholic acid) Safety and Dosing in Primary Biliary Cholangitis (PBC) Patients
Company to Host Conference Call at 8:30 a.m. ET
View HTML
Toggle Summary Intercept to Present at Upcoming Conferences
NEW YORK, Sept. 01, 2017 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced management will be participating in the
View HTML
Toggle Summary Intercept to Present at Upcoming Conference
NEW YORK, Aug. 10, 2017 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced management will be participating in the
View HTML